Valneva: new mixed data in Covid-19
According to these data, a booster dose was well tolerated in participants previously vaccinated with Pfizer-BioNTech or Moderna products, confirming the favorable safety profile of VLA2001, whether with a homologous or heterologous booster.
In contrast, the French vaccine company reports that, in this study, a booster dose with its product generated only a marginal increase in neutralizing antibody response.
Valneva is currently seeking regulatory approval for VLA2001 as a homologous and heterologous booster in people previously vaccinated with AstraZeneca's ChAdOx1-S.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction